Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 5/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481483 | 1.00 | LMNA (0.45) | LMNAEIF2AK4BACE1BACE2HDAC6 | |
| SCHEMBL22481384 | 0.91 | LMNA (0.45) | LMNABACE1BACE2HDAC6NAMPT | |
| SCHEMBL29668194 | 0.91 | LMNA (0.45) | LMNABACE1BACE2HDAC6NAMPT | |
| SCHEMBL22465253 | 0.86 | LMNA (0.50) | LMNAHDAC6MAPTHRH4HRH3 | |
| SCHEMBL22465410 | 0.86 | LMNA (0.50) | LMNAHDAC6MAPTHRH4HRH3 | |
| SCHEMBL22550809 | 0.84 | LMNA (0.40) | LMNABACE1BACE2HDAC6NAMPT | |
| SCHEMBL22481486 | 0.82 | NPY5R (0.42) | LMNABACE1BACE2HDAC6NAMPT | |
| SCHEMBL29668248 | 0.82 | NPY5R (0.42) | LMNABACE1BACE2HDAC6NAMPT | |
| SCHEMBL22481471 | 0.81 | TRPC3 (0.52) | LMNAEIF2AK4BACE1NAMPTMAPT | |
| SCHEMBL22481580 | 0.80 | NAMPT (0.38) | LMNANAMPTPARP1MAPTHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | LMNA 4022/4885EIF2AK4 659/4885BACE1 4186/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | LMNA 4022/4885EIF2AK4 659/4885BACE1 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.